Copyright
©The Author(s) 2015.
World J Orthop. Dec 18, 2015; 6(11): 977-982
Published online Dec 18, 2015. doi: 10.5312/wjo.v6.i11.977
Published online Dec 18, 2015. doi: 10.5312/wjo.v6.i11.977
Table 1 Patient demographics
Control group(n = 100) | TXA group(n = 100) | P value | |
Male/female | 49/51 | 44/56 | 0.47 |
Age in years | 62.57 ± 12.14 | 62.9 ± 12.6 | 0.86 |
THR/TKR | 60/40 | 52/48 | 0.25 |
Pre-operative Hgb | 13.61 ± 1.42 | 13.77 ± 1.41 | 0.43 |
Pre-operative Hct | 0.41 ± 0.04 | 0.41 ± 0.04 | 0.32 |
Pre-operative platelets | 253.01 ± 55.87 | 256.85 ± 69.75 | 0.67 |
- Citation: McGoldrick NP, O’Connor EM, Davarinos N, Galvin R, Quinlan JF. Cost benefit analysis of the use of tranexamic acid in primary lower limb arthroplasty: A retrospective cohort study. World J Orthop 2015; 6(11): 977-982
- URL: https://www.wjgnet.com/2218-5836/full/v6/i11/977.htm
- DOI: https://dx.doi.org/10.5312/wjo.v6.i11.977